Biointegration of soft tissue-inspired hydrogels on the chorioallantoic membrane: An experimental characterization
Materials Today Bio,
Год журнала:
2025,
Номер
unknown, С. 101508 - 101508
Опубликована: Янв. 1, 2025
Язык: Английский
An injectable, self-healing, anti-infective, and anti-inflammatory novel glycyrrhizic acid hydrogel for promoting acute wound healing and regeneration
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2025,
Номер
12
Опубликована: Янв. 10, 2025
Bacterial
infection,
a
complex
wound
microenvironment,
and
persistent
inflammatory
response
in
acute
wounds
can
result
delayed
healing
abnormal
scar
formation,
thereby
compromising
the
normal
function
aesthetic
appearance
of
skin
tissue.
This
issue
represents
one
most
challenging
problems
clinical
practice.
study
aims
to
develop
hydrogel
dressing
specifically
designed
for
treatment
wounds,
providing
immediate
effective
protection
affected
areas.
innovation
seeks
offer
novel
advanced
solution
management
wounds.
In
this
study,
composite
scaffold
was
synthesized
through
reaction
between
oxidized
glycyrrhizic
acid
carboxymethyl
chitosan
Schiff
base.
The
material
properties
were
systematically
characterized,
its
biocompatibility
antibacterial
efficacy
rigorously
evaluated.
A
rat
model
established
compare
multiple
groups,
assessing
impact
on
microenvironment
repair.
results
demonstrated
that
OGA-CMCS
exhibited
excellent
injectability,
biocompatibility,
properties.
It
capable
enhancing
which
turn
influenced
polarization
macrophages
from
M1
M2
phenotype,
mitigating
response,
promoting
angiogenesis
granulation
tissue
regeneration,
accelerating
healing.
successfully
developed
glycyrrhizin-based
dressing,
not
only
introduces
innovative
approaches
emergency
surface
defects
but
also
provides
an
experimental
foundation.
is
anticipated
contribute
significantly
addressing
relevant
challenges.
Язык: Английский
Application of allogeneic adult mesenchymal stem cells in the treatment of venous ulcers: A phase I/II randomized controlled trial protocol
PLoS ONE,
Год журнала:
2025,
Номер
20(5), С. e0323173 - e0323173
Опубликована: Май 15, 2025
Objective
To
evaluate
the
feasibility,
safety
and
efficacy
of
cutaneous
application
Bioengineered
Artificial
Mesenchymal
Sheet
(BAMS)
in
venous
leg
ulcers
(VLUs)
versus
conventional
treatment.
Methods
This
protocol
is
based
on
design
a
Phase
I/II,
multicenter,
randomized,
controlled,
open-label
clinical
trial
investigating
biological
dressing
supplemented
with
mesenchymal
stem
cells
(NCT05962931).
The
being
conducted
2
primary
care
units
within
Granada
Metropolitan
Health
District.
A
total
20
patients
VLUs
are
randomized
(1:1)
into
intervention
arms:
control
group
treatment
group.
consists
local
4
doses
BAMS,
administered
once
per
week,
while
receives
therapy.
Feasibility
will
be
assessed
ability
to
complete
administration
at
least
80%
Safety
evaluated
by
analyzing
incidence
adverse
effects
serious
effects.
Efficacy
terms
percentage
wound
closure
(measured
area
reduction),
macroscopic
assessment
lesion
(visual
analysis
RESVECH
2.0
scale),
growth
factors
inflammatory
cytokines
(ELISA
test),
pain
levels
(VAS
scale)
quality
life
(CIVIQ
20).
Results
If
confirmed,
BAMS-based
therapy
may
provide
an
effective
for
VLUs,
potentially
reducing
time
associated
complications.
could
significantly
enhance
patients’
due
regenerative
analgesic
properties
dressing.
Discussion
Given
activity
cells,
accelerated
healing
effect
expected
lead
shorter
times
chronic
wounds,
resulting
significant
benefits
patients,
healthcare
professionals,
overall
costs.
Trial
registration
NCT05962931.
Язык: Английский